Merck and Schering-Plough are looking to grab more of the $32 billion global cholesterol-drug market by jointly developing a new medicine combining their Zetia with rival Pfizer's blockbuster Lipitor.
The planned drug, meant to reduce bad cholesterol levels in two ways, could hit the market when Lipitor's patent expires in a few years, Merck and Schering-Plough said Monday.
More
Insider's view: Cant wait to hear the sales pitch for that one!
No comments:
Post a Comment